CA2875351C - Injectable antibiotic formulations and their methods of use - Google Patents

Injectable antibiotic formulations and their methods of use Download PDF

Info

Publication number
CA2875351C
CA2875351C CA2875351A CA2875351A CA2875351C CA 2875351 C CA2875351 C CA 2875351C CA 2875351 A CA2875351 A CA 2875351A CA 2875351 A CA2875351 A CA 2875351A CA 2875351 C CA2875351 C CA 2875351C
Authority
CA
Canada
Prior art keywords
composition
pnt
penethamate
oily vehicle
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2875351A
Other languages
English (en)
French (fr)
Other versions
CA2875351A1 (en
Inventor
Fadil Al Alawi
Olaf Bork
Rohit Jain
Karthigeyan Nanjan
Ian George Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer New Zealand Ltd
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49949085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2875351(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NZ613138A external-priority patent/NZ613138B2/en
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of CA2875351A1 publication Critical patent/CA2875351A1/en
Application granted granted Critical
Publication of CA2875351C publication Critical patent/CA2875351C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2875351A 2012-07-17 2013-07-16 Injectable antibiotic formulations and their methods of use Active CA2875351C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NZ60129912 2012-07-17
NZ601299 2012-07-17
NZ61017513 2013-05-03
NZ610175 2013-05-03
NZ613138A NZ613138B2 (en) 2013-07-12 Injectable antibiotic formulations and their methods of use
NZ613138 2013-07-12
PCT/NZ2013/000123 WO2014014363A1 (en) 2012-07-17 2013-07-16 Injectable antibiotic formulations and their methods of use

Publications (2)

Publication Number Publication Date
CA2875351A1 CA2875351A1 (en) 2014-01-23
CA2875351C true CA2875351C (en) 2021-08-31

Family

ID=49949085

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2875351A Active CA2875351C (en) 2012-07-17 2013-07-16 Injectable antibiotic formulations and their methods of use

Country Status (30)

Country Link
US (1) US10376585B2 (enExample)
EP (1) EP2874624B8 (enExample)
JP (1) JP6189437B2 (enExample)
KR (1) KR102113822B1 (enExample)
CN (1) CN104470517B (enExample)
AU (1) AU2013290826B2 (enExample)
BR (1) BR112014031083B1 (enExample)
CA (1) CA2875351C (enExample)
CL (1) CL2014003423A1 (enExample)
CO (1) CO7240359A2 (enExample)
CR (1) CR20140550A (enExample)
DK (1) DK2874624T3 (enExample)
DO (1) DOP2014000288A (enExample)
ES (1) ES2752034T3 (enExample)
HR (1) HRP20191730T1 (enExample)
HU (1) HUE046427T2 (enExample)
IL (1) IL236713B (enExample)
LT (1) LT2874624T (enExample)
MX (2) MX387668B (enExample)
MY (1) MY172561A (enExample)
NI (1) NI201400152A (enExample)
PH (1) PH12014502716A1 (enExample)
PL (1) PL2874624T3 (enExample)
PT (1) PT2874624T (enExample)
RU (1) RU2643327C2 (enExample)
SI (1) SI2874624T1 (enExample)
SV (1) SV2014004882A (enExample)
UA (1) UA118654C2 (enExample)
WO (1) WO2014014363A1 (enExample)
ZA (1) ZA201409322B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015014963B1 (pt) * 2012-12-20 2022-04-12 Alleva Animal Health Limited Formulação de suspensão injetável veterinária

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49768B1 (en) 1979-05-21 1985-12-11 Leo Pharm Prod Ltd 6beta-halopenicillanic acid derivatives
IE51516B1 (en) * 1980-10-06 1987-01-07 Leo Pharm Prod Ltd 1,1-dioxapenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate napsylate
IL64009A (en) 1980-10-31 1984-09-30 Rech Applications Therap Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them
IE51846B1 (en) * 1980-11-17 1987-04-15 Leo Pharm Prod Ltd Pharmaceutical preparation for veterinary use and an appliance containing it
DE3377064D1 (en) 1982-12-28 1988-07-21 Bayer Ag Stable aminoglycoside-penicillin injection formulation
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
CH693625A5 (it) * 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
US20040022815A1 (en) 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US6911441B2 (en) 2002-12-16 2005-06-28 Akzo Nobel N.V. Prolonged release pharmaceutical composition
CN1517090A (zh) 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
US20050143347A1 (en) * 2003-12-22 2005-06-30 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of accumulations of fat
DE102004025324A1 (de) * 2004-05-19 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US8679540B2 (en) * 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
WO2009052629A1 (en) * 2007-10-26 2009-04-30 Chemaphor Inc. Compositions and methods for enhancing immune response
PT2294012E (pt) * 2008-05-07 2014-10-15 Salix Pharmaceuticals Ltd Administração de um agente de limpeza intestinal e de um antibiótico para o tratamento de doença intestinal
US8501800B2 (en) * 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
CN101822637A (zh) 2009-12-31 2010-09-08 天津瑞普生物技术股份有限公司 一种含有β-内酰胺类抗生素的混悬注射剂
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
DE102010015143A1 (de) 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
KR20140047617A (ko) * 2011-06-23 2014-04-22 바이엘 뉴질랜드 리미티드 마크로사이클릭 락톤 및 레바미솔을 포함하는 항-기생충 조성물 및 기생충 감염의 치료 방법
WO2013095166A1 (en) 2011-12-23 2013-06-27 Bayer New Zealand Limited Antibiotic formulations
RU2627429C2 (ru) * 2012-02-27 2017-08-08 Байер Нью Зиленд Лимитед Составы с контролируемым высвобождением и способы их использования

Also Published As

Publication number Publication date
BR112014031083B1 (pt) 2021-06-15
CA2875351A1 (en) 2014-01-23
JP6189437B2 (ja) 2017-08-30
CO7240359A2 (es) 2015-04-17
DOP2014000288A (es) 2015-02-15
PH12014502716B1 (en) 2015-02-02
PL2874624T3 (pl) 2020-07-27
PH12014502716A1 (en) 2015-02-02
EP2874624A1 (en) 2015-05-27
MX358248B (es) 2018-08-10
UA118654C2 (uk) 2019-02-25
CN104470517B (zh) 2018-12-18
MX387668B (es) 2025-03-18
IL236713B (en) 2018-05-31
KR20150036092A (ko) 2015-04-07
RU2015105251A (ru) 2016-09-10
ZA201409322B (en) 2015-12-23
DK2874624T3 (da) 2019-11-11
EP2874624B1 (en) 2019-08-21
MX2014015927A (es) 2015-03-03
IL236713A0 (en) 2015-02-26
HRP20191730T1 (hr) 2019-12-13
KR102113822B1 (ko) 2020-05-22
NI201400152A (es) 2015-03-27
JP2015522608A (ja) 2015-08-06
US10376585B2 (en) 2019-08-13
ES2752034T3 (es) 2020-04-02
MY172561A (en) 2019-12-03
CN104470517A (zh) 2015-03-25
CL2014003423A1 (es) 2015-04-17
AU2013290826B2 (en) 2018-10-18
AU2013290826A1 (en) 2015-01-15
PT2874624T (pt) 2019-11-04
US20150174248A1 (en) 2015-06-25
SI2874624T1 (sl) 2020-02-28
EP2874624B8 (en) 2019-10-02
CR20140550A (es) 2015-02-05
EP2874624A4 (en) 2015-12-02
WO2014014363A1 (en) 2014-01-23
BR112014031083A2 (pt) 2017-06-27
RU2643327C2 (ru) 2018-01-31
HUE046427T2 (hu) 2020-03-30
SV2014004882A (es) 2016-11-11
LT2874624T (lt) 2019-12-10

Similar Documents

Publication Publication Date Title
US10493079B2 (en) Stable carfilzomib formulations
KR20190005183A (ko) 풀베스트란트 제제 및 그의 사용 방법
CA2875351C (en) Injectable antibiotic formulations and their methods of use
US9452155B2 (en) Injectable antibiotic formulations and their methods of use
NZ613138A (en) Injectable antibiotic formulations and their methods of use
NZ613138B2 (en) Injectable antibiotic formulations and their methods of use
TWI631948B (zh) 可注射型抗生素配方及其使用方法
NZ613240B2 (en) Injectable antibiotic formulations and their methods of use
EP2934524B1 (en) Penethamate veterinary injectable formulations
WO2024127418A1 (en) Injectable compositions of posaconazole
AU2024262981A1 (en) Injectable compositions of metolazone
WO2023148763A1 (en) Injectable pharmaceutical compositions of azole antifungal agents
AU2013364500A1 (en) Veterinary injectable formulations
NZ619101B2 (en) Veterinary Injectable Formulations
Simsek PARENTERAL SUSPENSION: AN OVERVIEW

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180706